Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Center Discord: 510(k) Review Process Is Flash Point At CDRH

This article was originally published in The Gray Sheet

Executive Summary

Details trickling into the public sphere about CDRH's device review process reveal heightened tension between reviewers and management over the proper response to a 510(k) submission

You may also be interested in...



Appeals Court Checks FDA On Its 510(k) Rescission Authority

In a 2-1 opinion, a federal appeals court ruled that FDA can’t use rescission to reverse a 510(k) clearance if the more time-consuming device reclassification process can accomplish the same ends. The decision sends a collagen knee scaffold device, which previously caused major contention inside FDA, back to the agency for a decision, but more court review might be ahead.

Regulatory News In Brief

CDRH issues simplified SOPs for resolving differences of scientific, regulatory or clinical opinion among staffers. More regulatory news.

Washington Roundup, August 2012

The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we report on recent FDA proposals to streamline the 510(k) and PMA submission processes and the ongoing investigation into FDA surveillance of CDRH employee whistleblowers.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel